Thrombosis research
-
Thrombosis research · Jan 2008
Randomized Controlled TrialSimvastatin and rosuvastatin mobilize Endothelial Progenitor Cells but do not prevent their acute decrease during systemic inflammation.
Endothelial Progenitor Cells (EPCs) are a specific subtype of haematopoietic stem cells that contribute to the repair of injured endothelium. Treatment with atorvastatin has been shown to increase EPC counts in patients with stable coronary artery disease. Numbers of circulating EPCs decrease in various inflammatory diseases. Thus, we hypothesized that short term statin pre-treatment may alter the acute change in EPC levels during systemic inflammation. ⋯ Statin therapy significantly increases EPCs within 96 hours and this may be a class effect. However, statins could not counteract the acute decrease in circulating EPCs after LPS infusion.
-
Thrombosis research · Jan 2008
ReviewWarfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate.
Bleeding can be a major problem in patients on oral anticoagulation therapy. Beriplex P/N is a prothrombin complex concentrate (PCC) that has been developed for the rapid reversal of anticoagulation in patients requiring immediate haemostatic control. Beriplex P/N contains high concentrations of the coagulation factors II, VII, IX and X, together with the inhibitors protein C and protein S, and it can be rapidly prepared and administered at an infusion rate of up to 8.0 mL/min. ⋯ There were no adverse events related to the rapid rate of infusion and, of the 8 serious adverse events reported; only 1 was regarded as being possibly related to treatment. No virus transmission was observed and changes in thrombogenicity markers were found to be transient and did not correspond to any clinically observed thromboembolic events. In conclusion, Beriplex P/N is an effective and well-tolerated therapy for rapid, complete and predictable reversal of anticoagulation in patients with acute bleeding or requiring emergency surgery.
-
Thrombosis research · Jan 2008
Venous thromboembolism in patients with pancreatic adenocarcinoma: lower incidence in Asian ethnicity.
Pancreatic adenocarcinoma is one of the cancers most frequently associated with venous thromboembolism (VTE), with the varying incidences of 10%-20% reported in Western countries. Asians are known to have a lower risk for VTE than Caucasians, but few studies have been conducted regarding the incidence of VTE in Asian cancer patients. ⋯ The incidence of VTE complications in Korean patients with advanced pancreatic cancer was 5.3%, which is lower than that observed in other ethnic groups. Our study warrants further prospective investigations on the incidence and mechanism of VTE and cerebral infarctions in cancer patients of different ethnic groups.
-
Thrombosis research · Jan 2008
Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry.
Patients with inadequate platelet inhibition by aspirin, referred to as aspirin resistance, might have an increased risk of suffering cardiovascular events. Therefore, identification of these patients by measuring platelet function is of great interest. Our objectives were to evaluate performance parameters of VerifyNow and to determine the agreement between VerifyNow and light transmission aggregometry (LTA) ad modum Born. ⋯ VerifyNow was highly repeatable, but further studies are needed to investigate the relevance of the cut-off level at 550 ARU for detecting aspirin resistance.